Form D · Biotechnology
Medical 21, Inc.
Plymouth, MN · CIK 0001673688
Offering snapshot reported Oct 23, 2026 · SEC filing
- Reported sold
- $550K Offering amount: $20M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 23, 2026 | Initial | $550,000 | No comparison | 3 | SEC filing |
| Aug 21, 2025 | Amendment | $10,017,500 | No comparison | 39 | SEC filing |
| Jul 29, 2024 | Amendment | $5,217,500 | $3,357,500vs Jul 31, 2023 | 29 | SEC filing |
| Jul 31, 2023 | Amendment | $1,860,000 | $1,430,000vs Apr 14, 2023 | 17 | SEC filing |
| Apr 14, 2023 | Initial | $430,000 | No comparison | 4 | SEC filing |
| Sep 20, 2022 | Initial | $2,500,000 | No comparison | 1 | SEC filing |
| Jan 12, 2021 | Amendment | $3,000,000 | $1,860,000vs Jan 16, 2020 | 15 | SEC filing |
| Jan 16, 2020 | Amendment | $1,140,000 | No comparison | 12 | SEC filing |
| Jan 8, 2019 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 1, 2018 | Initial | $750,000 | No comparison | 5 | SEC filing |
| Sep 1, 2017 | Initial | $250,000 | No comparison | 1 | SEC filing |
| May 19, 2016 | Initial | $200,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-602280
Source: Form D, filed Oct 23, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Erik Hermansen | Executive |
| Chaid Schwarz | Executive |
| Eric Solien | Executive |
| Andrea Sweeney | Executive |
| Manny Villafana | Director, Executive |
| Jeff Vreeman | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3700 Annapolis Lane North Suite 105
Plymouth, MN, 55447
Plymouth, MN, 55447